CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy

Europace

Volumn 16, Issue 1, 2014, Pages 71-80

  Paoletti Perini, Alessandro ^a   Bartolini, Simone ^a   Pieragnoli, Paolo ^a   Ricciardi, Giuseppe ^a   Perrotta, Laura ^a   Valleggi, Alessandro ^b   Vergaro, Giuseppe ^b   Michelotti, Federica ^c   Boggian, Giulio ^d   Sassone, Biagio ^d   Mascioli, Giosuè ^c   Emdin, Michele ^b   Padeletti, Luigi ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Fondazione Gabriele Monasterio   (Italy)

^c Humanitas Gavazzeni Hospital   (Italy)

^d SS Annunziata Hospital   (Italy)

Author keywords

Cardiac resynchronization therapy; CHA2DS2 VASc; CHADS2; Heart failure; Hospitalization; Mortality

Indexed keywords

ANGIOTENSIN II ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SUDDEN DEATH; VASCULAR DISEASE; VERY ELDERLY; AGE DISTRIBUTION; CHA2DS2-VASC; COMORBIDITY; DISEASE FREE SURVIVAL; HEART LEFT VENTRICLE FUNCTION; INCIDENCE; ITALY; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL; TREATMENT OUTCOME; UTILIZATION REVIEW;

CARDIAC RESYNCHRONIZATION THERAPY; CHA2DS2-VASC; CHADS2; HEART FAILURE; HOSPITALIZATION; MORTALITY;

AGE DISTRIBUTION; AGED; CARDIAC RESYNCHRONIZATION THERAPY; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; ITALY; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84891369836     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut190     Document Type: Article

References (34)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developedinne. Cardiac-resynchronization therapy with orwithout an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350: 2140-50.
2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberg L et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
3. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350: 2140-50.
4. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al.; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-95.
5. Bogale N, Priori S, Cleland JG, Brugada J, Linde C, Auricchio A et al.; Scientific Committee, National Coordinators, and Investigators. The European CRT survey: 1 year (9-15 months) follow-up results. Eur J Heart Failure 2012;14:61-73.
6. Savelieva I, Camm J. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 2004;S5-19.
7. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5.
8. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrialfibrillationinapopulation-basedcohort. The Framingham Heart Study. JAMA 1994;271:840-4.
9. Larned JM, Raja Laskar S. Atrial fibrillation and heart failure. Congest Heart Fail 2009; 15:24-30.
10. Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L et al.; Car-diological centers participating in Clinical Service Project. Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 2011;57:167-72.
11. Hayes DL, Boehmer JP, Day JD, Gilliam FR III, Heidenreich PA, Seth M et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011;8:1469-75.
12. Grönefeld GC, Mauss O, Li YG, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol 2000;11: 1208-14.
13. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH et al. Prognostic importanceofdefibrillator shocksinpatients with heart failure. N Engl J Med 2008; 359:1009-17.
14. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrialfibrillation: Incidence, prevalence, and predictionofstroke using the Congestive heart failure, Hypertension, Age.75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008;156:57-64.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137: 263-72.
16. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
17. Henriksson KM, Farahmand B, Asberg S, Terént A, Edvardsson N. First-ever atrial fibrillation documented after hemorrhagic or ischemic stroke: the role of the CHADS(2) score at the time of stroke. Clin Cardiol 2011;34:309-16.
18. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terént A, Edvardsson N. Survival after stroke-the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 2010;141:18-23.
19. Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E et al. CHADS2, CHA2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013;80:1009-17.
20. Naccarelli GV, Panaccio MP, Cummins G, Tu N. CHADS2 and CHA2DS2-VAScrisk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. Am J Cardiol 2012;109:1526-33.
21. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al.; Task Force for the Diagnosis and Treatment ofChronic Heart Failureofthe European Societyof Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26: 1115-40.
22. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al.; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatmentof acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
23. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J et al.; ESC Committee for Practice Guidelines. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association andthe European Heart Rhythm Association. Europace 2010;12:1526-36.
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations forchamberquantification:areport from the American Society of Echo-cardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
25. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;4:2731-8.
26. Moss AJ, Jackson Hall W, David S, Cannom DS, Klein H, Brown MW et al.; for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
27. Lilli A, Ricciardi G, Porciani MC, Perini AP, Pieragnoli P, Musilli N et al. Cardiac resyn-chronization therapy: gender related differences in left ventricular reverse remodeling. Pacing Clin Electrophysiol 2007;30:1349-55.
28. Zabarovskaja S, Gadler F, Braunschweig F, Sta°hlberg M, Hörnsten J, Linde C et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace 2012;14:1148-55.
29. Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart 2007;93:476-82.
30. Bai R, Di Biase L, Elayi C, Ching CK, Barrett C, Philipps K et al. Mortalityofheart failure patients after cardiac resynchronization therapy: identification of predictors. J Cardiovasc Electrophysiol 2008;19:1259-65.
31. Leclercq C, Padeletti L, Cihák R, Ritter P, Milasinovic G, Gras D et al.; CHAMP Study Investigators. Incidence of paroxysmal atrial tachycardias in patients treated with cardiac resynchronization therapy and continuously monitored by device diagnostics. Europace 2010;12:71-7.
32. Padeletti L, Paoletti Perini A, Gronda E. Cardiac resynchronization therapy: the issue of non-response. Heart Fail Rev 2012;17:97-105. Review.
33. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012; 163:260-7.
34. Rickard J, Kumbhani DJ, Gorodeski EZ, Baranowski B, Wazni O, Martin DO et al. Cardiac resynchronization therapy in non-left bundle branch block morphologies. Pacing Clin Electrophysiol 2010;33:590-5.